Stoke Therapeutics 株価情報 (NASDAQ: STOK)

最新ニュース Stoke Therapeutics (NASDAQ:STOK) 株価情報

Stoke Therapeutics

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Stoke Therapeutics Inc

Barclays analyst Seth Sigman maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $90 to $98.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Walmart, Raises Price Target to $98

Osisko Gold Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OR#NYSE">OR</a>) has outperformed the market over the past 5 years by 2.49% on an annualized basis producing an average annual return of 14.97%. Currently, Osisko Gold Royalties has a market capitalization of $3.47 billion. 
Buying $100 In OR: If an investor had bought $100 of OR stock 5 years ago, it would be worth $203.50 today based on a price of $18.60 for OR at the time of writing.
<h3>Osisko Gold Royalties's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736436616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Osisko Gold Royalties 5 Years Ago Would Be Worth This Much Today

Barclays analyst Seth Sigman maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Equal-Weight and raises the price target from $1088 to $1110.

ORLY

Barclays Maintains Equal-Weight on O'Reilly Automotive, Raises Price Target to $1110

RBC Capital analyst Gregory Renza maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Outperform and lowers the price target from $68 to $48.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

RBC Capital Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $48

Barclays analyst Karen Short maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Overweight and lowers the price target from $102 to $100.

Barclays Maintains Overweight on Dollar Gen, Lowers Price Target to $100

Barclays analyst Seth Sigman maintains Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) with a Equal-Weight and lowers the price target from $8 to $7.

BYON

Barclays Maintains Equal-Weight on Beyond, Lowers Price Target to $7

Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) owned search giant Google is the latest tech company to donate to Donald Trump's inauguration fund ahead of the highly anticipated<a href="https://www.benzinga.com/25/01/42801809/apple-ceo-tim-cook-reportedly-donates-1-million-to-trump-inauguration-joins-ranks-of-mark-zuckerberg-jeff-bezos-and-sam-altman"> Jan. 20 event.</a>
What Happened: Google announced a $1 million donation to Trump's inauguration,<a href="https://www.benzinga.com/general/politics/24/07/39826475/trumps-new-running-mate-j-d-vance-wants-to-break-up-google-could-2024-election-be-bad-for-big-te"> joining the ranks</a> of Meta Platforms, Amazon.com, Ford Motor Company and more.
Several tech billionaires including Apple CEO Tim Cook and OpenAI CEO Sam Altman have also announced $1 million donations on their own and not directly from their associated companies.
The donation by Google made on Monday was confirmed by <a href="https://www.politico.com/live-updates/2025/01/09/congress/google-donation-donald-trump-inauguration-00197233">Politico </a>on Thursday and comes as Alphabet CEO Sundar Pichai was among the tech moguls who met with Trump at Mar-A-Lago since his 2024 presidential election win.
"Google is pleased to support the 2025 inauguration, with a livestream on YouTube and a direct link on our homepage. We're also donating to the inaugural committee," Google's global head of government affairs and public policy Karen Bhatia told Politico.
Google previously donated $285,000 to the 2016 and 2020 inaugurations, a spokesperson told Politico. Google also previously promoted the inauguration on its homepage and YouTube.
Read Also: <a href="https://www.benzinga.com/24/12/42660866/trump-gets-ford-vehicles-1m-for-inauguration-will-musk-respond-or-could-he-ride-in-rival-vehicle">Trump Gets Ford Vehicles, $1M For Inauguration &#8211; Will Musk Respond Or Could He Ride In Rival Vehicle?</a>
Why It's Important: The donation from Google comes as the company has been targeted by the Department of Justice for <a href="https://www.benzinga.com/tech/24/11/42140450/doj-targets-google-chrome-poll-shows-64-oppose-alphabet-breakup-youtube-seen-as-top-prize">alleged monopolistic behavior </a>and could be forced to break up and spinoff assets like the Chrome browser.
While there's no certainty that a donation or a visit to Mar-A-Lago will sway the new administration or prevent such outcomes, changes to the DOJ&#8217;s leadership could potentially shift the company&#8217;s legal challenges.
Incoming Vice President J.D. Vance also previously said he <a href="https://www.benzinga.com/general/politics/24/07/39826475/trumps-new-running-mate-j-d-vance-wants-to-break-up-google-could-2024-election-be-bad-for-big-te">wants to break up </a>Google, which could make the company a target of the new administration.
Senator Ted Cruz (R-Texas) recently told Politico that Republicans would target Google's content moderation policies on the search engine and on YouTube.
GOOG Price Action: Alphabet stock closed at $195.39 Wednesday versus a 52-week trading range of $131.55 to $202.88. Alphabet stock is up 37% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/25/01/42880549/nvidia-ceo-jensen-huang-wants-to-congratulate-trump-at-mar-a-lago-but-hasnt-been-invited-yet">Nvidia CEO Jensen Huang Wants To Congratulate Trump At Mar-A-Lago, But Hasn&#8217;t Been Invited Yet</a></li>
</ul>
Photo: Shutterstock

Politics

Tech

GOOG

GOOGL

Google Donates $1 Million To Trump Inauguration, Plans YouTube Livestream: 'Pleased To Support'

RBC Capital analyst Daniel Perlin reiterates Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Outperform and maintains $25 price target.

Reiteration

FLYW

RBC Capital Reiterates Outperform on Flywire, Maintains $25 Price Target

Barclays analyst Seth Sigman maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Equal-Weight and lowers the price target from $95 to $89.

Barclays Maintains Equal-Weight on Best Buy Co, Lowers Price Target to $89

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) with a Outperform and maintains $31 price target.

CTNM

RBC Capital Reiterates Outperform on Contineum Therapeutics, Maintains $31 Price Target

Barclays analyst Matthew McClintock maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Overweight and raises the price target from $3024 to $3585.

Barclays Maintains Overweight on AutoZone, Raises Price Target to $3585

Barclays analyst Seth Sigman maintains Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Equal-Weight and lowers the price target from $66 to $54.

Barclays Maintains Equal-Weight on Advance Auto Parts, Lowers Price Target to $54

RBC Capital analyst Steven Shemesh reiterates Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Outperform and maintains $22 price target.

RBC Capital Reiterates Outperform on Albertsons Companies, Maintains $22 Price Target

RBC Capital analyst Sam Crittenden reiterates Capstone Copper (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CS#TSX">CS</a>) with a Outperform and maintains C$12 price target.

TSX:CS

RBC Capital Reiterates Outperform on Capstone Copper, Maintains C$12 Price Target

Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) has outperformed the market over the past 5 years by 7.91% on an annualized basis producing an average annual return of 20.39%. Currently, Unum Gr has a market capitalization of $13.32 billion. 
Buying $1000 In UNM: If an investor had bought $1000 of UNM stock 5 years ago, it would be worth $2,512.92 today based on a price of $72.95 for UNM at the time of writing.
<h3>Unum Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736435709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Unum Gr 5 Years Ago Would Be Worth This Much Today

On Thursday, Nokia Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) disclosed that Openreach has selected its One Network Platform to build an open-<a target="_blank" href="https://www.globenewswire.com/news-release/2025/01/09/3006821/0/en/Nokia-and-Openreach-introduce-intent-based-networking-to-build-an-open-access-network-accelerating-UK-fiber-broadband-rollout.html" rel="noreferrer noopener">access </a>fiber network across the U.K.
Nokia&#8217;s solution is projected to enable Openreach to build a large-scale, multi-service network with lower power and space requirements. The architecture supports various deployment models, ensuring providers can seamlessly connect users to Openreach&#8217;s fiber network.
Notably, Openreach&#8217;s broadband network connects users to around 300 providers, offering high-speed fiber services in cities, towns, villages, and remote areas across the U.K.
Nokia&#8217;s One Network Platform helps meet the growing demand by offering flexibility and scale, while reducing the number of exchange buildings needed.
Built using Nokia&#8217;s One Network Platform, the network will enable Openreach to achieve its goal of connecting 25 million premises by the close of 2026, addressing the growing demand for high-speed broadband.
Using Nokia&#8217;s Altiplano and NSP network controllers, Openreach can automate fiber connectivity and simplify operations with a unified service interface and reduces OSS complexity by 85%, while providing real-time telemetry for better network performance insights.
Last week, Nokia, along with Intuitive Machines, Inc., successfully integrated the Lunar Surface Communication System into <a target="_blank" href="https://www.benzinga.com/25/01/42856421/from-earth-to-the-moon-intuitive-machines-and-nokia-launch-4glte-network" rel="noreferrer noopener">the&nbsp;IM-2 mission lander, Athena</a>.
Investors can gain exposure to NOK stock via&nbsp;iShares U.S. Digital Infrastructure and Real Estate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDGT#NYSE">IDGT</a>) and&nbsp;First Trust Indxx NextG ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTG#NASDAQ">NXTG</a>).
Price Action: NOK shares closed higher by 0.65% at $4.66 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/12/42535215/nokia-supercharges-indias-broadband-with-ishan-tech-taps-zscaler-to-upgrade-cloud-protection" target="_blank" rel="noreferrer noopener">Nokia Supercharges India&#8217;s Broadband with Ishan Tech; Taps Zscaler To Upgrade Cloud Protection</a></li>
</ul>

Equities

iShares U.S. Digital Infrastructure and Real Estate ETF

IDGT

NXTG

Openreach Taps Nokia For UK Fiber Expansion: Details

RBC Capital analyst Darko Mihelic upgrades Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) from Sector Perform to Outperform and raises the price target from C$97 to C$103.

Upgrades

TSX:CM

RBC Capital Upgrades Canadian Imperial Bank to Outperform, Raises Price Target to C$103

RBC Capital analyst Darko Mihelic upgrades Canadian Imperial Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CM#NYSE">CM</a>) from Sector Perform to Outperform and raises the price target from $97 to $103.

RBC Capital Upgrades Canadian Imperial Bank to Outperform, Raises Price Target to $103

RBC Capital analyst Darko Mihelic upgrades Bank of Montreal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMO#NYSE">BMO</a>) from Sector Perform to Outperform and raises the price target from $133 to $161.

RBC Capital Upgrades Bank of Montreal to Outperform, Raises Price Target to $161

RBC Capital analyst Darko Mihelic upgrades Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) from Sector Perform to Outperform and raises the price target from C$133 to C$161.

TSX:BMO

RBC Capital Upgrades Bank of Montreal to Outperform, Raises Price Target to C$161

Tracking Baker Brothers Portfolio - Q3 2024 Update

Chardan initiated coverage of Stoke Therapeutics (STOK) with a Buy rating and $24 price target The firm cites the potential of the company's lead a...

Stoke Therapeutics initiated with a Buy at Chardan

GeneDx ($WGS) is among the best performing small cap stocks for 2024, posting over 2600% gain. The company analyzes the complete DNA of a person, a...

GeneDx (WGS), An Emerging Powerhouse in Genomics Sees Explosive Growth

Stoke Therapeutics (STOK) announced alignment with global regulatory agencies on the design of the company's Phase 3 EMPEROR study of zorevunersen ...

Stoke Therapeutics finalizes EMPEROR study program with regulatory agencies

An announcement from Stoke Therapeutics ( ($STOK) ) is now available. Stoke Therapeutics has secured alignment with global regulatory agencies for ...

Stoke Therapeutics Gains Regulatory Alignment for Phase 3 Study

Stoke Therapeutics to initiate late-stage study for the treatment of Dravet syndrome

Analyst Joseph Stringer from Needham maintained a Buy rating on Stoke Therapeutics (STOK – Research Report) and keeping the price target at $22.00....

Buy Rating on Stoke Therapeutics Driven by Promising Phase 3 Trial and Financial Stability

Chardan keeps a Buy rating and $24 price target on Stoke Therapeutics (STOK) after the company provided a "long-awaited" update for its Phase 3 stu...

Stoke Therapeutics negative reaction after STK-001 update overdone, says Chardan

Stoke Therapeutics (STOK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from ...

Stoke Therapeutics' Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early Results

Leerink Partners analyst Marc Goodman has maintained their bullish stance on STOK stock, giving a Buy rating yesterday. Marc Goodman's rating is ba...

Positive Outlook on Stoke Therapeutics: Strategic Alignment and Promising Data Reinforce Long-Term Growth Potential

ABCL

ACAD

ALGS

ALKS

ARGNF

ARGX

AVTE

BCYC

BEIGF

BGNE

BIIB

BMEA

CERS

DNLI

EWTX

GLUE

HOOK

IGMS

IMCR

IMTX

INCY

INSM

KALA

KNSA

KYMR

MDGL

NRIX

PRAX

RARE

REPL

RVMD

RYTM

SGMT

SMMT

STOK

TCRX

TRDA

TSVT

VTVT

Press Releases

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Comments

Stoke Therapeutics

ニュース

最新ニュース Stoke Therapeutics (NASDAQ:STOK) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル